New York State Teachers Retirement System Increases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

New York State Teachers Retirement System boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 100,427 shares of the biopharmaceutical company’s stock after purchasing an additional 907 shares during the period. New York State Teachers Retirement System owned approximately 0.09% of Regeneron Pharmaceuticals worth $105,573,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Stephens Consulting LLC acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $26,000. Sachetta LLC increased its holdings in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the last quarter. Crewe Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at approximately $28,000. Lynx Investment Advisory acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $33,000. Finally, Family Firm Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth $33,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on REGN. JPMorgan Chase & Co. dropped their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Morgan Stanley cut their price objective on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Piper Sandler lifted their target price on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a research report on Friday, August 23rd. Wells Fargo & Company lowered their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, October 22nd. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,101.00.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN traded up $1.10 during midday trading on Wednesday, reaching $928.43. The company’s stock had a trading volume of 79,847 shares, compared to its average volume of 503,870. The company has a market cap of $102.35 billion, a price-to-earnings ratio of 24.56, a price-to-earnings-growth ratio of 3.20 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a one year low of $772.84 and a one year high of $1,211.20. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The company has a 50 day moving average price of $1,077.78 and a 200 day moving average price of $1,041.48.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. During the same period last year, the company posted $8.79 EPS. The company’s revenue was up 12.3% compared to the same quarter last year. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.6 EPS for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares of the company’s stock, valued at $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.